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Abstract: HIV-associated lipodystrophy is a term used to describe a constellation of body 
  composition (lipoatrophy and lipohypertrophy) and metabolic (dyslipidemia and insulin   resistance) 
alterations that accompany highly active antiretroviral therapy. These changes, which resemble 
metabolic syndrome, have been associated with a variety of adverse outcomes including acceler-
ated cardiovascular disease. The body composition and metabolic changes appear to cluster in 
HIV infection, although they are distinct alterations and do not necessarily coexist. Epidemiologi-
cal studies have demonstrated multiple pathogenic influences associated with host, disease, and 
treatment-related factors. The adverse treatment effects were more prominent in early regimens; 
continued drug development has led to the application of metabolically safer regimens with equal 
or greater potency than the regimens being replaced. Disease-related factors include HIV infec-
tion as well as inflammation, immune activation, and immune depletion. The body composition 
changes promote anxiety and depression in patients and may affect treatment adherence. Treat-
ment of dyslipidemia and alterations in glucose metabolism is the same as in non-HIV-infected 
individuals. Lipoatrophy is managed by strategic choice of antivirals or by antiviral switching, and 
in some cases by plastic/reconstructive surgery. Lipohypertrophy has been managed mainly by 
lifestyle modification, ie, a hypocaloric diet and increased exercise.  A growth hormone releasing 
factor, which reduces central fat, has recently become available for clinical use.
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Introduction
The term lipodystrophy is used to describe a diverse group of disorders characterized 
by a constellation of body composition and metabolic alterations.1 Changes in body 
composition include lipoatrophy, which is complete or partial loss of adipose tissue 
compartments, and lipohypertrophy, which is a pathological accumulation of adipose 
tissue in distinct body compartments. Lipoatrophy and lipohypertrophy may or may 
not coexist. Metabolic abnormalities include insulin resistance and dyslipidemia. 
Hepatic steatosis may also be recognized. The severity of these comorbidities usually 
correlates with the degree of adipose tissue loss. Accompanying complications may 
include hypertension, proteinuric kidney disease, acanthosis nigricans, and polycystic 
ovary syndrome.
Lipodystrophy may be inherited or acquired; the former is rarely seen (Table 1). By 
far, the most common type of lipodystrophy seen in the last 2 decades is an acquired 
form that occurs in HIV-infected individuals treated with highly active antiretroviral 
therapy (HAART), where reported prevalence rates range from a few percent to over 
80%.2 A major confounding factor in this field has been uncertainty as to whether HIV/AIDS - Research and Palliative Care 2011:3 submit your manuscript | www.dovepress.com
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the body composition and metabolic alterations represent a 
single syndrome or a variety of coexisting abnormalities, or 
even if some of the alterations are related to the development 
of metabolic syndrome. For the purpose of this article, the 
body composition and metabolic alterations will be grouped 
together and referred to as “lipodystrophy.”
With the recognition that HIV production could be 
suppressed but not eradicated, the focus of therapy in the 
mid-1990s was to convert the infection from a uniformly 
fatal disease into a long-term, manageable condition. This 
accomplishment was reported in 1998, with the seminal pub-
lication from the Multicenter AIDS Cohort Study (MACS) 
associating a dramatic drop in death rate from AIDS with 
widespread application of HAART in the United States.3 
However, the frequent occurrence of diabetes mellitus, insulin 
resistance, dyslipidemia, lipoatrophy, central lipohypertrophy 
accumulation,4 and premature cardiovascular disease was 
also reported at the time. As excess morbidity and mortality 
from these complications increase the risks and decrease 
the benefits of HAART, vigorous efforts have been made to 
define the metabolic and other health risks associated with 
HIV infection and HAART, as well as to develop safer agents 
and treatment regimens.
Clinical presentation
Body composition
The clinical diagnosis of lipodystrophy is usually made on 
the basis of physical examination, by recognizing changes 
in the sizes of different body fat compartments, especially 
the presence of lipoatrophy. Lipoatrophy is seen as a loss of 
subcutaneous fat in the extremities or face. Loss of fat in the 
lower extremities may lead to an appearance of prominent 
veins in the legs, reaching to the upper thighs, while fat loss 
in the face is especially prominent in the cheeks. Early in 
the HAART era, it was often difficult to distinguish fat loss 
from lipoatrophy or from wasting related to protein-energy 
malnutrition. One key difference is that lean mass and skeletal 
muscle mass are normal in patients with lipodystrophy but 
are low in malnourished patients. While obvious in full-blown 
cases, inspection lacks diagnostic sensitivity. It has been 
estimated that a loss of around one-third of subcutaneous fat 
is needed before lipoatrophy becomes clinically apparent.5 
The required losses may be even higher in patients who are 
obese at treatment initiation.
Although the diagnosis does not depend on quantitating 
the degree of adipose tissue loss, estimations can be made 
in clinical settings. The most practical and cost-effective, 
and hence frequently used, modalities are anthropometric 
measurements of biceps, triceps, and subscapular skin folds, 
as well as hip and waist circumferences. More accurate 
methods, which offer superior objectivity and precision, are 
dual energy X-ray absorptiometry and the cross-sectional 
imaging techniques, magnetic resonance imaging (MRI) 
and computerized tomography (Figure 1). These techniques 
are limited to research settings due to high costs and to lack 
of third-party insurance coverage, availability for everyday 
clinical practice, and generally accepted normal ranges 
and definitions of abnormality. Ultrasonography is another 
potential alternative to estimate intra-abdominal fat content; 
it has accuracy and precision and yet is affordable as well 
as accessible.
A gain in truncal and upper body fat content (specifically, 
visceral fat content) may be seen in treated patients in the 
presence or absence of lipoatrophy. In women, the increase 
in fat may include the breasts. The health effects of truncal 
obesity are well known to clinical medicine. Jean Vague,6 
a French investigator, defined two distinct morphologic 
obesity subtypes in women: android or upper body obesity, 
which was associated with insulin resistance, diabetes, and 
cardiovascular disease, and gynecoid or lower body obesity, 
which was not associated with these adverse outcomes. 
The key observation was that the differences in outcome 
were independent of actual fat mass, so that it was the body 
distribution of fat and not the obesity per se that predicted 
poor outcomes.
The interrelationships between the changes in the sizes 
of subcutaneous and visceral fat compartments were initially 
uncertain. Data from the Fat Redistribution and Metabolic 
Change in HIV Infection (FRAM) study, which compared 
the results of body composition and metabolic measurements 
Table 1 Types of lipodystrophy
Acquired
Acquired generalized lipodystrophy
Acquired partial lipodystrophy
HIV-associated lipodystrophy
Localized lipodystrophy
Inherited
Congenital generalized lipodystrophy
  Type 1
  Type 2
Familial partial lipodystrophy
Dunnigan variety
PPAR-γ mutations
Mandibuloacral dysplasia
Type A lipodystrophy
Type B lipodystrophy
Note: Summarized from Garg.1 
Abbreviation: PPAR-γ, peroxisome proliferator-activated receptor gamma.HIV/AIDS - Research and Palliative Care 2011:3 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
137
HIV lipodystrophy
in HIV- and non-HIV-infected subjects, showed that HIV-
infected men who reported a loss of body fat had significantly 
less subcutaneous adipose tissue (SAT), as measured by 
whole-body MRI, than non-HIV-infected controls.7 However, 
HIV-infected men who did not report a loss of body fat also 
had significantly less SAT than did controls, so that lipoa-
trophy was associated with HIV infection. The differences 
in women were smaller but were in the same direction.8 In 
contrast to the SAT results, the results of visceral adipose 
tissue (VAT) measurements showed that mean values were 
lower in the HIV-infected group than in the controls. These 
results differed from the expectation that the loss in SAT 
in the HIV group would be associated with a gain in VAT 
(ie, fat redistribution). It should be noted that the results of this 
cross-sectional study do not point to a cause for the   difference 
(ie, viral infection versus antiretroviral agents, or other 
  factors). In a later, longitudinal analysis of the MACS cohort, 
investigators showed a similar gain in waist circumference in 
both HIV-infected and control men.9 Thus, it appears that an 
increase in truncal fat content is relatively common but is not 
necessarily related to HIV infection or to its treatment.
Metabolic alterations
Metabolic alterations – namely, dyslipidemia and insulin 
resistance – frequently accompany HAART therapy and have 
become a widespread concern due to their link to cardio-
vascular disease. Elevated triglyceride levels are seen most 
commonly with the use of protease inhibitor (PI) therapy. 
Mild hypercholesterolemia is observed in 30%–50% of 
patients. However, dyslipidemia was seen commonly in the 
pre-antiretroviral era.10 In the pre-HAART era, increased 
triglyceride levels were associated with increased interferon 
alpha concentrations in HIV patients.11 While abnormalities 
in glucose metabolism were an uncommon complications of 
PI therapy in initial clinical trials (2%–5%), the US Food and 
Drug Administration (FDA) reported the onset of diabetes 
in patients treated with PI therapy in 1997.12
Pathogenic mechanisms
PIs were initially implicated as the primary cause of the 
observed changes.4 Direct effects of PIs on serum lipids 
and glucose metabolism were shown in non-HIV-infected 
volunteers.13,14 However, it soon was recognized that the 
detection of lipoatrophy preceded the application of PI 
therapy.15 Thymidine analog nucleoside reverse transcriptase 
inhibitors (NRTIs) were shown to promote lipoatrophy as 
well as metabolic alterations. In addition, non-nucleoside 
reverse transcriptase inhibitors (NNRTIs) have been shown 
to affect serum lipid concentrations.
The results of epidemiological studies performed since 
the late 1990s suggested the presence of multiple pathogenic 
mechanisms, including disease, host, and treatment-related 
influences (Table 2). Importantly, there were distinctions in 
the relative importance of various factors as well as much 
overlap, suggesting that lipodystrophy is not a single process 
but rather a condition whose expression is of multifactorial 
origin. The FRAM study has been particularly instrumental 
in demonstrating distinctions among its various components. 
While some continue to classify the condition as a single dis-
ease, most investigators and treating physicians now believe 
that the interrelationships among the body composition and 
metabolic alterations are loose and that the abnormalities can 
be evaluated and managed individually.
Figure 1 Computerized tomography scans of (A) a healthy adult and (B) a patient 
with coexisting lipoatrophy and lipohypertrophy. In comparison with the healthy adult, 
the patient with coexisting lipoatrophy and lipohypertrophy has less subcutaneous 
adipose tissue and an increase in intra-abdominal (visceral) adipose tissue.HIV/AIDS - Research and Palliative Care 2011:3 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
138
Singhania and Kotler
be to a dyslipidemic condition. The same may be said 
of insulin resistance, truncal obesity, or other aspects of 
health and disease.
There is both clinical and experimental evidence for 
direct metabolic effects of antiretroviral agents. Some PIs 
reversibly inhibit glucose uptake into muscle and adipose 
tissue cells at the level of the glucose transport molecule 
GLUT4.17 PIs also may affect hepatic very-low-density 
lipoprotein secretion through an inhibition of intracellular 
apoprotein B degradation.18
NRTIs, especially thymidine analogs, may also have 
direct toxicity. Fialuridine, the first agent tested in chronic 
hepatitis B infection was the precedent for NRTI toxicity. The 
drug was virologically effective but it led to a high incidence 
of subacute liver failure with symptomatic lactic acidosis.19 
The toxic effect was found to be mitochondrial toxicity 
related to inhibition of the effect of DNA polymerase γ, the 
DNA polymerase involved in mitochondrial function. Many 
clinical studies have linked NRTI therapy with mitochondrial 
toxicity, including lactic acidosis in HIV infection. The major 
cause of lipoatrophy was shown to be thymidine analog NRTI 
therapy, based on studies of antiretroviral-naïve subjects on 
their initial HAART regimens.20,21 Mitochondrial dysfunc-
tion also promotes insulin resistance and dyslipidemia.22,23 
Depletion of mitochondrial DNA has been shown in both 
in vitro and in vivo studies, and partial reversal both of the 
mitochondrial DNA depletion and of clinical toxicity has 
been demonstrated after switching to alternative antiviral 
agents.24
NNRTIs promote apoprotein A1 synthesis, which is 
associated with increased HDL cholesterol concentration.25 
On the other hand, entry and integrase inhibitors appear to 
be free of metabolic toxicities.
Many studies have demonstrated genetic predisposi-
tions to development of body composition and metabolic 
abnormalities. The potential for genetically based differ-
ential susceptibility to NRTI toxicity was demonstrated 
by the observation that lactic acidosis in patients receiving 
thymidine analog NRTI therapy occurred mainly in African-
American women, even though the relative size of the treat-
ment population at the time was reasonably low.
A single nucleotide polymorphism in the resistin gene 
was shown to be associated with a cluster of metabolic 
alterations including insulin resistance, dyslipidemia, and 
lipoatrophy in antiretroviral-naïve patients receiving an 
initial HAART regimen.26 Of note, pretreatment serum lipid 
and insulin concentrations were higher in the subgroup that 
developed body composition and metabolic alterations than 
Table 2 HIV-associated lipodystrophy: epidemiological associations
Host
Age
Sex
ethnicity
Individual genetic susceptibility
BMI
Diet
exercise
Comorbidities
Therapy
Specific agent
Duration
Disease
Duration
Severity of immune depletion
Magnitude of immune reconstitution
Abbreviation: BMI, body mass index.
Another major uncertainty is the relative importance of 
the various influences. In general, the effects of specific anti-
viral agents in promoting body composition and metabolic 
alterations have diminished over the past 5–7 years as drug 
development has led to the application of less-toxic   regimens. 
In addition, the effects of inflammation and immune acti-
vation related to the underlying viral infections (eg, HIV, 
hepatitis C, cytomegalovirus, and so forth) have become 
more apparent, even in patients being successfully treated 
with HAART. The role of individual host susceptibilities, 
especially the role of specific genetic polymorphisms, is also 
increasingly recognized.
As noted, certain metabolic alterations such as hyper-
triglyceridemia were seen in the pre-HAART era, and even 
in the era prior to the development of antiviral therapies.10 
An important observation was made by investigators of 
the MACS cohort, who had the opportunity to follow 
approximately 50 individuals from a period prior to HIV 
seroconversion through initiation and follow-up of HAART 
therapy.16 A fall in total, high-density lipoprotein (HDL), 
and low-density lipoprotein (LDL) cholesterol concen-
trations was noted after seroconversion and persisted as 
immune function declined. Initiation of HAART led to 
increases in total and LDL cholesterol, but only to near 
preinfection values for LDL cholesterol. The data were 
interpreted to show that the rise in serum LDL choles-
terol concentration was related to reversal of an effect 
of infection in lowering serum lipids. Thus, a mild to 
moderate rise in total or LDL cholesterol concentration 
after HAART initiation may be viewed as a return to prior 
health, rather than as evidence of drug   toxicity. However, 
if dyslipidemia preceded HIV infection, the return would HIV/AIDS - Research and Palliative Care 2011:3 submit your manuscript | www.dovepress.com
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in those that did not. Several other polymorphisms have 
been shown to affect the serum lipid response to antiviral 
therapy. Based on these data, it is likely that the develop-
ment of severe metabolic alterations is related to an interac-
tion among the viral infection, antiviral medications, and 
underlying predisposition to metabolic alterations. Many 
other single-  nucleotide polymorphisms have been linked to 
various elements of lipodystrophy, including genes related 
to apoproteins, lipid metabolism, proinflammatory cytokines, 
drug efflux transport, and apoptosis. Mitochondrial haplo-
types also may influence the susceptibility to developing 
lipodystrophy as they do in NRTI-associated neuropathy.
Several investigators have noted similarities between 
HIV-associated lipodystrophy and metabolic syndrome as 
seen in non-HIV-infected individuals, though some studies 
have shown that HIV-infected patients are more likely to have 
hypertriglyceridemia and are less likely to be hypertensive. 
In non-HIV-infected patients with metabolic syndrome, 
there is now substantial evidence linking inflammation and 
atherosclerosis.27 Many studies have documented persist-
ing inflammation and immune activation in HIV infection, 
even in patients on suppressive HAART therapy.28 Chronic 
inflammation and immune activation are believed to play 
a role in long-term adverse outcomes, including mortality, 
cardiovascular disease, neurocognitive decline, osteopenia, 
and frailty, among others.
The relative roles of viral infection and its treatment in 
the genesis of cardiovascular disease in HIV infection were 
illustrated by the results of the Strategies for Management of 
Antiretroviral Therapy (SMART) study.29 This was a seminal 
study that directly compared the effects of continuous viral 
suppression with HAART and with limiting the exposure 
to antiviral therapy by starting and stopping therapy based 
upon CD4 count. At the time the study was conceived, many 
believed that limiting antiviral exposure would decrease 
adverse outcomes, but the opposite was observed. Not only 
was symptomatic cardiovascular disease more common with 
intermittent treatment but also viral rebound was directly 
associated with several relevant alterations, including eleva-
tions in pro-inflammatory cytokines, coagulation factors, and 
decreased HDL cholesterol concentrations in this and another 
similarly designed study.30,31
The role of the underlying viral infection in promoting 
cardiovascular disease was corroborated in the AIDS   Clinical 
Trials Group (ACTG) study 5152s, a metabolic substudy 
of ACTG 5142, which compared class-sparing regimens 
in antiretroviral-naïve subjects.32 Flow-mediated dilatation, 
a measure of endothelial function, was measured at baseline 
and after 12 weeks. Baseline values were abnormally low 
and rose moderately on treatment. Importantly, values rose 
similarly in all arms of the trial, and changes in endothelial 
function correlated with changes in plasma viral load, rather 
than any specific antiviral agent (Figure 2).
Clinical significance
The identification of lipodystrophy has had profound implica-
tions on the management of HIV . Its recognition as a side effect 
of HAART led to a re-evaluation of the appropriate time to start 
therapy (specifically, delaying initiation of HAART) and also to 
various modifications in therapies for HIV – namely, switching 
therapies, stopping therapy, and intermittent treatment all had 
in their rationale, at least in part, the desire to minimize drug 
exposure so as to avoid metabolic alterations and associated 
adverse outcomes including cardiovascular disease.
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Figure 2 Change in endothelial function in the AIDS Clinical Trials Group study 5142.32 This study examined a class-sparing strategy and a substudy examined endothelial 
function as flow-mediated dilatation (FMD). FMD was impaired at baseline and improved during highly active antiretroviral therapy. The improvement was independent of a 
specific regimen and bore no relationship to baseline viral load; however, it had a significant association with the decrease in viral load. 
Notes: Data as change in flow-mediated diameter, expressed as percent. Within-group differences: P , 0.005 for PI-sp and NNRTI-sp regimens; P = 0.015 for NRTI-sp regimen. 
*Data expressed as percent and presented as absolute change compared with pretreatment values. 
Abbreviations: NNRTI, non-nucleoside reverse transcriptase inhibitor; NRTI, nucleoside reverse transcriptase inhibitor; PI, protease inhibitor; sp, sparing.HIV/AIDS - Research and Palliative Care 2011:3 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
140
Singhania and Kotler
Various quality-of-life studies in HIV lipodystrophy 
have generally shown that patients enjoy a good quality of 
life, including good physical functioning, whereas com-
mon complaints manifesting as anxiety and depression are 
related mostly to the stigma associated with morphologic 
changes.33,34 HIV-infected patients may refuse therapy or 
reduce treatment compliance as a result of or in order to avoid 
these side effects. As a result, the patient may experience 
rebound in viral load or the development of viral resistance. 
This will eventually lead to disease progression and even 
to an increased risk of disease transmission, possibly by a 
drug-resistant viral strain.
The changes associated with lipodystrophy (body fat 
redistribution, dyslipidemia, and insulin resistance) are 
associated with cardiovascular disease. Many cohort studies 
have implicated an increased risk for developing symptom-
atic cardiovascular disease.35,36 However, the relative risk of 
developing symptomatic cardiovascular disease is uncertain 
since these studies lack internal control groups. Analysis of 
the D:A:D cohort suggests that the Framingham equation for 
cardiovascular risk modestly underestimates the actual risk 
in HIV-infected individuals.37 That being said, the benefits 
of HAART therapy far outweigh the cardiovascular risk in 
the form of reduced risk of illness and death, and antiviral 
therapy certainly should not be withheld for fear of promot-
ing cardiovascular disease.
Diagnosis
There has been considerable debate about the appropriate 
diagnostic criteria for this syndrome, but little consensus 
has been reached. A multifactorial equation, the Lipodystro-
phy Severity Grading Scale, was developed to discriminate 
between patients generally agreed to have and patients gener-
ally agreed not to have the syndrome, and has the potential 
to act as a tool for case definition.38 However, this equation 
requires extensive evaluation using technologies not easily 
accessed clinically, and it is not helpful therapeutically, since 
therapies are based upon the specific alterations rather than 
lipodystrophy per se. Other scales have been developed for 
assessing subcutaneous lipoatrophy, facial lipoatrophy, and 
central fat accumulation, as well as quality of life, anxiety, 
and depression. These scales have been applied more in 
research than in clinical management. As a consequence, 
practitioners of HIV medicine have become familiar with 
practice standards for internal medicine in addition to those 
related specifically to the management of HIV infection.
Several sets of guidelines for metabolic alterations have 
been published.39,40 In general, the recommendations   parallel 
those developed for similar metabolic alterations in the 
absence of HIV infection.
Therapeutic options
There are five basic possible strategies to manage the body 
composition and/or metabolic changes: (1) avoid by strate-
gic choice of antiviral agents; (2) do not intervene; (3) stop 
HAART; (4) switch HAART; and (5) treat the individual 
abnormalities while continuing HAART. For some practi-
tioners, viral suppression is of paramount importance; clini-
cians treat the various abnormalities individually and do not 
change an effective antiviral regimen. Others believe that the 
metabolic alterations are dangerous. In the past, clinicians 
have sometimes discontinued therapy completely; presently, 
switching to an alternative antiviral regimen, if there is one 
available, is more common.
The notion of treatment in lipodystrophy is complicated. 
Treatment includes both prevention and corrective therapy. 
It is important to define the specific outcomes, which range 
from asymptomatic changes in serum lipid concentrations 
to fatal cardiovascular disease, when analyzing specific 
  treatments. In addition, the effect sizes of the various treat-
ments vary considerably.
The overall risks and benefits of HAART in relation 
to the outcome of cardiovascular disease were examined 
in the SMART study.29 This large, international, multicenter 
trial was designed to determine which of two different 
HIV treatment strategies, continuous viral suppression or 
drug conservation, would result in greater overall clinical 
benefit. In the drug conservation group, HAART inter-
rupted until CD4+ cell count fell below 250 cells/mm3, 
then restarted and   continued until the CD4 was above 
350 cells/mm3. Over 5400 subjects were enrolled at 318 
clinical sites in 33   countries over 4 years. Randomization 
was halted in January 2006 when the data safety monitoring 
board reported an increased relative risk of several adverse 
events in the drug conservation group. Further analyses 
showed significant increases in the risk of death, disease 
progression, myocardial infarction, as well as non-AIDS 
events. Other studies demonstrated that the discontinuation 
of HAART was associated with adverse effects in many 
surrogate markers for cardiovascular disease, including cir-
culating levels of HDL cholesterol, D-dimer, interleukin-6, 
and other biomarkers,30 highlighting the role of infection 
and inflammation in promoting atherosclerosis and other 
clinical complications.
It is important to note that the SMART study was 
performed between 2002 and 2006. Progress in drug HIV/AIDS - Research and Palliative Care 2011:3 submit your manuscript | www.dovepress.com
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  development has led to the development of many treatment 
regimens that are relatively free of metabolic toxicities, so 
the decisions on treatment switching are limited to ones 
with prior drug toxicity or few remaining treatment options. 
Of course, other therapies like weight control and smoking 
cessation must be stressed in all cases as they likely have 
a greater influence on outcome than do individual antiret-
roviral agents.
Many randomized clinical trials have been performed 
comparing the body composition and metabolic effects of 
different antiretroviral combinations in the management of 
previously antiretroviral-naïve subjects. In these studies, 
NRTIs, PIs, and NNRTIs have been randomized on a fixed 
backbone, while current and future studies will evaluate 
entry and integrase inhibitors in a similar fashion. In addi-
tion, class-sparing regimens have been evaluated. In general, 
studies have shown that newer generations of NRTIs are 
highly effective in avoiding the development of lipoatrophy, 
newer generations of PIs are highly effective in avoiding 
the development of dyslipidemia and insulin resistance, and 
the newer classes of antiretroviral agents are free of serious 
metabolic toxicities.
Most early studies involved a switch from PI- to NNRTI-
based HAART, without a change in nucleoside therapy and 
with variable benefits related to the specific therapies being 
stopped and started.41 However, no changes in body compo-
sition were seen in these studies. Other studies, evaluating 
a switch from thymidine analog NRTI to other agents (eg, 
tenofovir or abacavir) led to a mild increase in limb fat and 
SAT, as well as to metabolic improvements. Other treatment 
switches have been performed looking at the effects of newer 
classes of agents (ie, integrase inhibitors), as well as studies 
designed to evaluate treatment simplification strategies. In 
general, the effect size for preventing lipoatrophy is greater 
than the effect size seen after switching treatment, suggesting 
a degree of irreversibility in the damage.
Treatment of dyslipidemia
Standard dietary modifications have only a modest effect on 
serum lipid concentrations, though a few studies showed that 
standard dietary advice led to prevention of weight gain and 
less dyslipidemia than no intervention.42,43 Several studies 
have shown that the fibrate subclass of antihyperlipidemia 
medications decreases serum triglyceride concentrations but 
does not significantly affect serum cholesterol concentrations. 
In contrast, HMG-CoA reductase inhibitors (statins) decrease 
serum cholesterol concentrations and, to a lesser extent, trig-
lyceride concentrations. Despite these effective agents, the 
goals of clinical management of hyperlipidemia, as defined 
by National Cholesterol Education Program criteria, are 
often not reached in HIV-infected patients.42 It is impor-
tant to remember that metabolism of some hypolipidemic 
medications is affected by ritonavir, through inhibition of 
cytochrome-mediated metabolism (CYP3A4). Consequently, 
pravastatin and rosuvastatin have become the drugs of choice 
for the treatment of dyslipidemia as they lack this specific 
drug–drug interaction, though they are not necessarily free 
of all interactions.
Treatment of insulin resistance  
and diabetes mellitus
The management of insulin resistance and diabetes   mellitus 
should be the same in HIV-infected and noninfected patients, 
with the exception of possible antiviral regimen change. There 
is no official guideline for the pharmacologic management of 
insulin resistance in HIV- or non-HIV-infected   individuals. 
Diabetes mellitus in HIV-infected individuals may be either 
ketosis prone or ketosis resistant, although the latter is the more 
common. Diet and oral agents are usually adequate to success-
fully manage most of the patients with this syndrome.
Treatment of lipoatrophy
Of all of the treatment-associated side effects, lipoatrophy 
has received the most attention. The most important advance 
in its management was the realization of the role played 
by thymidine analog NRTIs. Studies demonstrating a lack 
of developing lipoatrophy with alternative therapies led to 
the strategic avoidance of the problem.20,21 The situation 
in patients with clinically detectable lipoatrophy is less 
promising, as drug switching leads to only partial reversal 
of lipoatrophy. It has been suggested that the duration of 
thymidine analog therapy may determine if and how much 
reversibility is possible. Studies have also shown that deple-
tion in mitochondrial DNA and mitochondrial dysfunction 
do not reverse completely, even long after thymidine analog 
therapy has been discontinued. Several agents, such as thi-
azolidinediones and uridine, have shown biologic activity 
in SAT and promote relatively minor amounts of reversal 
of lipoatrophy; however, there are no strong recommenda-
tions or guidelines support for such treatments. Several 
forms of plastic surgery have been applied to patients with 
facial lipoatrophy, with aesthetic success for several types 
of fillers;44 other therapies, including implants, have been 
used anecdotally in other body sites. The major drawback 
of plastic surgery is the lack of insurance coverage in many 
needy patients.HIV/AIDS - Research and Palliative Care 2011:3 submit your manuscript | www.dovepress.com
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Treatment of lipohypertrophy
Two well-known factors that affect total body and regional 
fat mass in non-HIV-infected subjects are diet and exercise. 
There has been relatively little study of these lifestyle changes 
in HIV-infected individuals. Both resistance exercise and a 
moderate exercise program were shown to reduce waist cir-
cumference and/or truncal fat content. A study of hypocaloric 
feeding and combined resistance and aerobic exercise in 
obese, HIV-infected women led to a significant loss of body 
weight and some VAT; however, there was no improvement 
of metabolic alterations, either insulin sensitivity or serum 
lipid concentrations.45 As these studies were performed rela-
tively early in the HAART era, it was speculated that mito-
chondrial dysfunction related to thymidine analog therapy 
prevented the metabolic improvement. Studies performed in 
subjects not receiving thymidine analogs have shown benefits 
of diet and exercise as well as insulin-sensitizing agents.46
Human growth hormone has been shown to significantly 
reduce VAT in non-HIV-infected men with truncal obesity.47 
Similar effects on VAT were seen in studies of HIV-infected 
subjects,48 although the drug did not gain FDA approval for 
that indication. However, a growth hormone-releasing factor 
has also been shown to significantly decrease VAT49 and the 
FDA did approve the drug for that indication. As opposed 
to growth hormone, therapy is metabolically neutral. Limits 
in the effect size, cost, and need for daily self-injection will 
be major limiting factors in its application.
Conclusion
The development and application of HAART has had a profound 
effect on the natural course of HIV infection in the developed 
world and, increasingly, in the developing world. The recogni-
tion of adverse outcomes other than those related to immune 
deficiency has broadened the tasks required of the HIV caregiver 
to include primary care, especially in preventive cardiology. 
Unraveling the secrets surrounding HIV-associated lipodystro-
phy has provided important lessons about the interaction among 
infection, inflammation, and metabolic dysregulation.
Disclosure
The authors report no conflicts of interest in this work.
References
1.  Garg A. Acquired and inherited lipodystrophies. N Engl J Med. 2004; 
350:1220–1234.
2.  Safrin S, Grunfeld C. Fat distribution and metabolic changes in patients 
with HIV infection. AIDS. 1999;13:2493–2505.
3.  Palella FJ, Baker RK, Moorman AC, et al. Mortality in the highly active 
antiretroviral therapy era: changing causes of death and disease in the 
HIV outpatient study. J Acquir Immune Defic Syndr. 1998;43:27–34.
  4.  Carr A, Samaras K, Burton S, et al. A syndrome of peripheral 
  lipodystrophy, hyperlipidemia and insulin resistance in patients receiv-
ing protease inhibitors. AIDS. 1998;12:F51–F58.
  5.  Podzamczer D, Ferrer E, Martínez E, et al. How much fat loss is 
needed for lipoatrophy to become clinically evident. AIDS Res Hum 
  Retroviruses. 2009;25:563–567.
  6.  Vague J. The degree of masculine differentiation of obesities: a factor 
determining predisposition to diabetes, atherosclerosis, gout, and uric 
calculous disease. Am J Clin Nutr. 1956;4:20–23.
  7.  Bacchetti P, Gripshover B, Grunfeld C, et al. Fat distribution in men 
with HIV infection. J Acquir Immune Defic Syndr. 2005;40:121–131.
  8.  Study of fat redistribution and metabolic change in HIV infection 
(FRAM). Fat distribution in women with HIV infection. J Acquir 
Immune Defic Syndr. 2006;42:562–571.
  9.  Brown TT, Chu H, Wang Z, et al. Longitudinal increases in waist 
circumference are associated with HIV-serostatus, independent of 
antiretroviral therapy. AIDS. 2007;21:1731–1738.
  10.  Grunfeld C, Pang M, Doerrler W, et al. Lipids, lipoproteins, triglyceride 
clearance, and cytokines in human immunodeficiency virus infection 
and the acquired immunodeficiency syndrome. J Clin Endocrinol 
Metab. 1992;74:1045–1052.
  11.  Grunfeld C, Kotler DP, Shigenaga JK, et al. Circulating interferon-α 
levels and hypertriglyceridemia in the acquired immunodeficiency 
syndrome. Am J Med. 1991;90:154–162.
  12.  Lumpkin MM. FDA public health advisory: reports of diabetes and 
hyperglycemia in patients receiving protease inhibitors for the treatment 
of human immunodeficiency virus (HIV). Rockville, MD: US Food and 
Drug Administration; June 11, 1997.
  13.  Purnell JQ, Zambon A, Knopp RH, et al. Effect of ritonavir on 
lipids and post-heparin lipase activities in normal subjects. AIDS. 
2000;14:51–57.
  14.  Noor MA, Lo JC, Mulligan K, et al. Metabolic effects of indinavir in 
healthy HIV-seronegative men. AIDS. 2001;15:F11–F18.
  15.  Maia BS, Engelson ES, Wang J, Kotler DP. Antiretroviral therapy 
affects the composition of weight loss in HIV infection: implications 
for clinical nutrition. Clin Nutr. 2005;24:971–978.
  16.  Riddler SA, Smit E, Cole SR, et al. Impact of HIV infection and HAART 
on serum lipids in men. JAMA. 2003;289:2978–2982.
  17.  Murata H, Hruz PW, Mueckler M. The mechanism of insulin resis-
tance caused by HIV protease inhibitor therapy. J Biol Chem. 2000; 
275:20251–20254.
 18.  Liang JS, Distler O, Cooper DA, et al. HIV protease inhibitors protect apoli-
poprotein B from degradation by the proteosome: a potential mechanism for 
protease inhibitor-induced hyperlipidemia. Nat Med. 2001;7:1327–1331.
  19.  McKenzie R, Fried MW, Sallie R, et al. Hepatic failure and lactic aci-
dosis due to fialuridine (FIAU), an investigational nucleoside analogue 
for chronic hepatitis B. N Engl J Med. 1995;333:1099–1105.
  20.  Gallant JE, Staszewski S, Pozniak AL, et al. Efficacy and safety of 
tenofovir DF vs stavudine in combination therapy in antiretroviral-naive 
patients: a 3-year randomized trial. JAMA. 2004;292:191–201.
  21.  Gallant JE, DeJesus E, Arribas JR, et al. Tenofovir DF, emtricitabine, 
and efavirenz vs zidovudine, lamivudine, and efavirenz for HIV . N Engl 
J Med. 2006;354:251–260.
  22.  Blumer RM, van Vonderen MG, Sutinen J, et al. Zidovudine/lamivudine 
contributes to insulin resistance within 3 months of starting combination 
antiretroviral therapy. AIDS. 2008;22:227–236.
  23.  Fleischman A, Johnson S, Systrom DM, et al. Effects of a nucleoside 
reverse transcriptase inhibitor, stavudine, on glucose disposal and mito-
chondrial function in muscle of healthy adults. Am J Physiol Endocrinol 
Metab. 2007;292:E1666–E1673.
  24.  Martin A, Smith SE, Carr A, et al. Reversibility of lipoatrophy in HIV-
infected patients 2 years after switching from a thymidine analogue to 
abacavir: the MITOX Extension Study. AIDS. 2004;18:1029–1036.
  25.  Franssen R, Sankatsing RR, Hassink E, et al. Nevirapine increases 
high-density lipoprotein cholesterol concentration by stimulation of 
apolipoprotein A-1 production. Arterioscler Thromb Vasc Biol. 2009; 
29:1336–1341.HIV/AIDS - Research and Palliative Care
Publish your work in this journal
Submit your manuscript here: http://www.dovepress.com/hivaids---research-and-palliative-care-journal
HIV/AIDS - Research and Palliative Care is an international, peer-
reviewed open-access journal focusing on advances in research in HIV , 
its clinical progression and management options including antiviral 
treatment, palliative care and public healthcare policies to control 
viral spread. The journal welcomes original research, basic science, 
clinical & epidemiological studies, reviews & evaluations, expert 
opinion & commentary, case reports & extended reports. The manu-
script management system is completely online and includes a very 
quick and fair peer-review system. Visit http://www.dovepress.com/ 
testimonials.php to read real quotes from published authors.
HIV/AIDS - Research and Palliative Care 2011:3 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
Dovepress
143
HIV lipodystrophy
  26.  Ranade K, Geese WJ, Noor M, et al. Genetic analysis implicates resistin 
in HIV lipodystrophy. AIDS. 2008;22:1561–1568.
  27.  Ross R. Atherosclerosis: an inflammatory disease. N Engl J Med. 
1999;340:115–126.
  28.  Deeks SG. HIV infection, inflammation, immunosenescense, and aging. 
Annu Rev Med. 2011;62:141–155.
  29.  El Sadr WM, Lundgren JD, Neaton JD, et al. CD4+ count-guided interrup-
tion of antiretroviral treatment. N Engl J Med. 2006;355:2283–2296.
  30.  Kuller LH, Tracy R, Belloso W, et al. Inflammatory and coagulation 
biomarkers and mortality in patients with HIV infection. PLoS Med. 
2008;5:e203.
  31.  Calmy A, Gayet-Ageron A, Montecucco F, et al. HIV increases markers 
of cardiovascular risk: results from a randomized, treatment interruption 
trial. AIDS. 2009;23:929–939.
  32.  Torriani F, Komarow L, Parker RA, et al. Endothelial function in 
human immunodeficiency virus-infected antiretroviral-naive subjects 
before and after starting potent antiretroviral therapy: the ACTG (AIDS 
  Clinical Trials Group) Study 5152s. J Am Coll Cardiol. 2008;52: 
569–576.
  33.  Marin A, Casado JL, Aranzabal L, et al. Validation of a specific question-
naire on psychological and social repercussions of the lipodystrophy 
syndrome in HIV-infected patients. Qual Life Res. 2006;15:767–775.
  34.  Ammassari A, Murri R, Pezzotti P, et al. Self-reported symptoms and 
medication side effects influence adherence to highly active antiretro-
viral therapy in persons with HIV infection. J Acquir Immune Defic 
Syndr. 2001;28:445–449.
  35.  Friis-Moller N, Sabin CA, Weber R, et al. Combination antiretro-
viral therapy and the risk of myocardial infarction. N Engl J Med. 
2003;349:1993–2003.
  36.  Klein D, Hurley LB, Quesenberry CP Jr, Sidney S. Do protease inhibi-
tors increase the risk for coronary heart disease in patients with HIV 
infection? J Acquir Immune Defic Syndr. 2002;30:471–477.
  37.  Law MG, Friis-Moller N, El-Sadr WM, et al. The use of the Framingham 
equation to predict myocardial infarctions in HIV-infected patients: 
comparison with observed events in the D:A:D Study. HIV Med. 2006; 
7:218–230.
  38.  Carr A, Emery S, Law M, et al. An objective case definition of lip-
odystrophy in HIV-infected adults: a case-control study. Lancet. 2003; 
361:726–735.
  39.  Schambelan M, Benson CA, Carr J, et al. Management of metabolic 
complications associated with antiretroviral therapy for HIV-1   infection: 
recommendations of an International AIDS Society-USA panel. 
J Acquir Immune Defic Syndr. 2002;31:257–275.
  40.  Wohl DA, McComsey G, Tebas P, et al. Current concepts in the   diagnosis 
and management of metabolic complications of HIV infection and its 
therapy. Clin Infect Dis. 2006;43:645–653.
  41.  Martínez E, Arnaiz JA, Podzamczer D, et al. Substitution of 
  nevirapine, efavirenz, or abacavir for protease. Inhibitors in patients 
with human immunodeficiency virus infection. N Engl J Med. 2003; 
349:1036–1046.
  42.  Lazzaretti R, Pinto-Ribeiro J, Kummer R, Polanczyk C, Sprinz E. 
Dietary intervention when starting HAART prevents the increase in 
lipids independently of drug regimen: a randomized trial [Abstract 
WEAB303]. Oral abstract session: 4th IAS Conference on HIV 
Pathogenesis, Treatment and Prevention; 2007 Jul 22–25; Sydney, 
Australia.
  43.  Joy T, Keough HM, Hadigan C, et al. Dietary fat intake and relation-
ship to serum lipid levels among HIV-infected subjects with metabolic 
abnormalities in the era of HAART. AIDS. 2007;21:1591–1600.
  44.  Valantin MA, Aubron-Olivier C, Ghosn J, et al. Polylactic acid implants 
(New-Fill) to correct facial lipoatrophy in HIV-infected patients: results 
of the open-label study VEGA. AIDS. 2003;17:2471–2477.
  45.  Engelson ES, Agin D, Werber-Zion G, et al. Effects of a diet and exer-
cise weight loss regimen on obese, HIV-infected women. Metabolism. 
2006;55:1327–1336.
  46.  Yarasheski KE, Cade WT, Overton ET, et al. Exercise training augments 
the peripheral insulin-sensitizing effects of pioglitazone in HIV-infected 
adults with insulin resistance and central obesity. Am J Physiol Endo-
crinol Metab. 2011;300:E243–E251.
  47.  Johannsson G, Marin P, Lonn L, et al. Growth hormone treatment of 
abdominally obese men reduces abdominal fat mass, improves glucose 
and lipoprotein metabolism, and reduces diastolic blood pressure. J Clin 
Endocrinol Metab. 1997;82:727–734.
  48.  Kotler DP, Muurahainen N, Grunfeld C, et al. Effects of growth 
hormone on abnormal visceral adipose tissue accumulation and 
dyslipidemia in HIV-infected patients. J Acquir Immune Defic Syndr. 
2004;35:239–254.
  49.  Falutz J, Allas S, Blot K, et al. Effects of a growth hormone releasing 
factor analogue (growth hormone releasing hormone) on body com-
position and metabolic indices in HIV-infected patients. N Engl J Med. 
2007;357:2359–2370.